The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The company is already marketing the 4 mg and 10 mg strengths
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
The product will be manufactured at Lupin's facility in Goa, India.
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Subscribe To Our Newsletter & Stay Updated
